For Healthcare Professionals

COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies

clipboard-pencil

About the study

Phase 1 open label sequential dose escalation and cohort expansion study evaluating the safety, tolerability and preliminary antitumor activity of COM902 as monotherapy and in combination with COM701 in subjects with advanced malignancies.
user-3

Who can take part

You may be eligible to participate in the study if you meet the following criteria:

INCLUSION CRITERIA

  1. Subjects with histologically/cytologically confirmed advanced malignancy (solid tumor) who must have exhausted all available standard therapy, or not a candidate for standard therapy.
  2. Subject is able to provide written, informed consent before initiation of any study related procedures, and is able, in the opinion of the investigator, to comply with all the requirements of the study.
  3. Subject has Eastern Cooperative Oncology Group (ECOG) performance status 0-1. For Triplet combination MSS-CRC:
  4. Histologically confirmed adenocarcinoma of the colon/rectum
  5. Stage IV disease
  6. MSS-CRC status by an FDA approved test
  7. Disease progression with no more than 3 prior lines of treatment including fluroropyrimidines, irinotecan, and oxaliplatin For Triplet combination ovarian cancer:
  8. Advanced epithelial ovarian, fallopian tube, or primary peritoneal carcinoma
  9. Platinum resistant ovarian cancer (PROC) defined as disease recurrence < 6 months after completion of a platinum-containing regimen: Patients with primary platinum refractory disease are ineligible. Primary platinum refractory disease is defined as progression of disease prior to completion of 1st line platinum therapy or immediately following (≤ 3 months following last date of chemotherapy)
  10. Received ≤3 prior lines for PROC; maintenance bevacizumab or PARP are not included as a line of therapy
  11. Subjects who have received PARP inhibitor therapy are eligible Key

EXCLUSION CRITERIA

  1. Prior treatment with a TIGIT inhibitor.
  2. Prior treatment with an inhibitor of PVRIG
  3. Symptomatic interstitial lung disease or inflammatory pneumonitis.
  4. History of immune-related events that required immunotherapy treatment discontinuation For Triplet combination expansion cohorts (MSS-CRC and PROC): -Prior treatment with an anti-PD-1/PD-L1/2, anti-CD96 antibody, anti-OX-40 antibody, anti-CD137 antibody, anti-LAG3, anti-TIM3, anti-CTLA4 antibody.
pin location

Study Locations

Enter your ZIP code/Postal code/PIN code to locate study sites near you:

How to Apply


Contact the study center to learn if this study is a good match for you.
Phone iconCall ‪+1 415 373 0781Email iconEmail Study Center

Study’s details


Contition

Advanced Cancer,Breast Cancer,Colon Cancer,HNSCC,Lung Cancer,MSS-CRC,Microsatellite Stable Colorectal Carcinoma,Multiple Myeloma,Ovarian Cancer,Plasma Cell Neoplasm

Age

18+

Phase

Phase 1

Participants needed

110

Est. Completion Date

Jun 2024

Treatment type

Interventional


Sponsor

Compugen Ltd

ClinicalTrials.gov identifier

NCT04354246

Study number

CPG-02-101

Understanding Clinical Trials


Get answers to your questions about clinical trials.What is a clinical research?What does taking part in clinical trials involve?What should I ask the trial doctor?
Vector

Interested?

Sign up to save your favorites, 
receive newsletters, resources, and alerts 
about clinical trials related to your conditions of interest.